A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms PACIFIC 6
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

24 Oct 2023 Results of final analysis (As of Mar 20, 2023) assessing the efficacy and safety of Durvalumab in patients with unresectable stage III NSCLC, presented at the 48th European Society for Medical Oncology Congress.
11 Oct 2023 According to an AstraZeneca media release, data from this will be presented at the European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023.
17 Apr 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight